P00519.4
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
124,955 Da
NCBI Official Full Name
Tyrosine-protein kinase ABL1
NCBI Official Synonym Full Names
ABL proto-oncogene 1, non-receptor tyrosine kinase
NCBI Official Synonym Symbols
ABL; JTK7; p150; c-ABL; v-abl; c-ABL1; bcr/abl [Similar Products]
NCBI Protein Information
tyrosine-protein kinase ABL1; proto-oncogene c-Abl; bcr/c-abl oncogene protein; Abelson tyrosine-protein kinase 1; c-abl oncogene 1, receptor tyrosine kinase; proto-oncogene tyrosine-protein kinase ABL1; v-abl Abelson murine leukemia viral oncogene homolog 1
UniProt Protein Name
Tyrosine-protein kinase ABL1
UniProt Synonym Protein Names
Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Proto-oncogene c-Abl; p150
UniProt Synonym Gene Names
UniProt Entry Name
ABL1_HUMAN
NCBI Summary for ABL1/ABL2
This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. [provided by RefSeq, Aug 2014]
UniProt Comments for ABL1/ABL2
Abl: an ubiquitously expressed and highly conserved proto-oncogenic tyrosine kinase. c-Abl protein is distributed in both the nucleus and the cytoplasm of cells. Negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. It has been implicated in regulation of cell proliferation, differentiation, apoptosis, cell adhesion and stress response. The Philadephia chromosome translocation t(9;22)(q34;q11) creates a Bcr-Abl fusion protein, responsible for 90% of chronic myelogenous leukemia (CML) and ~25% of acute lymphoblastic leukemia (ALL). Inhibitors: Gleevec (imatinib, Glivec), Dasatinib. Two alternatively-spliced isoforms have been described.
Protein type: EC 2.7.10.2; Protein kinase, TK; Protein kinase, tyrosine (non-receptor); Kinase, protein; Oncoprotein; TK group; Abl family
Chromosomal Location of Human Ortholog: 9q34.1
Cellular Component: nucleoplasm; nuclear membrane; extrinsic to internal side of plasma membrane; mitochondrion; perinuclear region of cytoplasm; cytoplasm; leading edge; nucleolus; nucleus; cytosol; actin cytoskeleton
Molecular Function: actin monomer binding; protein C-terminus binding; non-membrane spanning protein tyrosine kinase activity; magnesium ion binding; protein kinase activity; actin filament binding; protein binding; syntaxin binding; DNA binding; protein-tyrosine kinase activity; manganese ion binding; mitogen-activated protein kinase binding; nicotinate-nucleotide adenylyltransferase activity; SH3 domain binding; ATP binding; receptor binding
Biological Process: DNA damage induced protein phosphorylation; positive regulation of apoptosis; cerebellum morphogenesis; negative regulation of BMP signaling pathway; B cell receptor signaling pathway; elevation of cytosolic calcium ion concentration; transitional one stage B cell differentiation; regulation of endocytosis; negative regulation of mitotic cell cycle; neuromuscular process controlling balance; cell cycle arrest; positive regulation of oxidoreductase activity; spleen development; mitosis; positive regulation of I-kappaB kinase/NF-kappaB cascade; negative regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of peptidyl-tyrosine phosphorylation; muscle cell differentiation; DNA damage response, signal transduction resulting in induction of apoptosis; positive regulation of osteoblast proliferation; negative regulation of ubiquitin-protein ligase activity; autophagy; response to oxidative stress; actin cytoskeleton organization and biogenesis; axon guidance; peptidyl-tyrosine phosphorylation; alpha-beta T cell differentiation; platelet-derived growth factor receptor signaling pathway; mitochondrial depolarization; positive regulation of mitotic cell cycle; Bergmann glial cell differentiation; regulation of transcription, DNA-dependent; collateral sprouting; cell differentiation; B cell proliferation during immune response; regulation of cell adhesion; epidermal growth factor receptor signaling pathway; cell migration; mismatch repair; thymus development; activated T cell proliferation; DNA damage response, signal transduction; B-1 B cell homeostasis; protein modification process; regulation of cell proliferation; microspike biogenesis; innate immune response; positive regulation of muscle cell differentiation; regulation of autophagy; negative regulation of cell-cell adhesion; positive regulation of release of sequestered calcium ion into cytosol; blood coagulation; response to DNA damage stimulus
Disease: Leukemia, Chronic Myeloid
Research Articles on ABL1/ABL2
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-ABL1/ABL2 antibody
Pathways associated with anti-ABL1/ABL2 antibody
Diseases associated with anti-ABL1/ABL2 antibody
Disease Name |
Pubmed Publications |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Antibodies |
>408 publications with ABL1/ABL2 and Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
Precursor Cell Lymphoblastic Leukemia-Lymphoma Antibodies |
>166 publications with ABL1/ABL2 and Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Cell Transformation, Neoplastic Antibodies |
>68 publications with ABL1/ABL2 and Cell Transformation, Neoplastic |
Carcinogenesis Antibodies |
>65 publications with ABL1/ABL2 and Carcinogenesis |
Anemia Antibodies |
>22 publications with ABL1/ABL2 and Anemia |
Neoplasms, Experimental Antibodies |
>17 publications with ABL1/ABL2 and Neoplasms, Experimental |
Disease Models, Animal Antibodies |
>15 publications with ABL1/ABL2 and Disease Models, Animal |
Cardiovascular Diseases Antibodies |
>13 publications with ABL1/ABL2 and Cardiovascular Diseases |
Nervous System Diseases Antibodies |
>10 publications with ABL1/ABL2 and Nervous System Diseases |
Adenocarcinoma Antibodies |
>8 publications with ABL1/ABL2 and Adenocarcinoma |
Organs/Tissues associated with anti-ABL1/ABL2 antibody
|